Opportunities and Challenges in Global Innovation Policies

By HEOR Staff Writer

March 27, 2024

Introduction:

The global healthcare landscape is evolving rapidly, with significant implications for the biopharmaceutical industry and global innovation policies in healthcare. Two key areas of focus are the World Health Organisation’s (WHO) Pandemic Agreement and the discussions at international meetings on intellectual property (IP) and pandemic readiness.

WHO Pandemic Agreement: A Mixed Bag for Innovators

The WHO Pandemic Agreement aims to establish a global consensus on strengthening pandemic prevention, preparedness, and response. This agreement has the potential to bolster global health and pandemic readiness, but it also presents several challenges.

On the positive side, the agreement promotes a comprehensive “One Health” approach, aiming to enhance disease surveillance and strengthen healthcare systems worldwide. It also seeks to empower regulatory authorities to expedite authorisation for pandemic-related products and highlights the need to combat misleading health information.

However, the agreement also contains provisions that could undermine biopharmaceutical innovation and collaboration. These include linking pathogen sharing with access to medical countermeasures as well as monetary benefits, waiving intellectual property rights, and centralising the WHO’s role in vaccine and therapeutic manufacturing. The centralised role of the WHO in vaccine and pharmaceutical supply chains is complex as it lacks the expertise and data to make vital, timely, and costly decisions. This can affect non-pandemic medicines, products, and lives.

International Meetings: A Crucible for American Innovation

International meetings at major multilateral organisations (MLOs) could significantly impact American innovation, health outcomes, and pandemic preparedness. These discussions focus on policies related to IP and pandemic readiness. World leaders are seeking consensus to finalise agreement in May. The agreement should promote biopharmaceutical research, development, and manufacture, and avoid actions that discourage innovation and collaboration.

Notably, the World Trade Organisation’s (WTO) TRIPS Waiver Extension and the World Intellectual Property Organisation’s (WIPO) negotiations on Genetic Resources (GRs) could have far-reaching implications for American researchers and the healthcare industry.

Global Innovation Policies in Healthcare

As these discussions and negotiations unfold, the importance of innovation and collaboration in addressing global crises becomes increasingly clear. Policymakers should learn from the COVID-19 pandemic and focus on policies that support innovation rather than undermine it.

The Way Forward: Supporting Innovation and Collaboration

Moving forward, it is crucial for policymakers to engage with private sector stakeholders to ensure more equitable access to vaccines and therapeutics in future health emergencies. The biopharmaceutical industry has much to contribute and should be a key partner in these discussions.

Conclusion:

As we navigate this rapidly evolving landscape, it’s crucial to remember that innovation and collaboration are key to improving global health. Policymakers must focus on supporting these elements to ensure we are prepared for future health emergencies.

Reference url

Recent Posts

NICE Kidney Cancer Guideline: Enhancing Biopsy Use to Minimize Unnecessary Surgery

By João L. Carapinha

September 18, 2025

The NICE kidney cancer guideline represents a major shift in how renal cell carcinoma is diagnosed and managed in the UK. How does this guideline change the standard of kidney cancer care? By emphasizing more accurate diagnosis—especially the targeted use of kidney biopsies—it aims to avoid unnec...
CAPVAXIVE Pneumococcal Vaccine Delivers Strong Immune Response in At-Risk Youth

By HEOR Staff Writer

September 17, 2025

What makes the CAPVAXIVE pneumococcal vaccine significant for children and adolescents at higher risk for pneumococcal disease? The CAPVAXIVE pneumococcal vaccine (21-valent conjugate vaccine) demonstrated robust immune responses and broad serotype coverage in Merck’s Phase 3 STRIDE-13 trial. ...
Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascular Perks

By HEOR Staff Writer

September 16, 2025

Novo Nordisk’s oral semaglutide (Rybelsus®) has received a significant label update from the European Medicines Agency (EMA). It is now the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved in the EU for type 2 diabetes with proven cardiovascular benefits. This deci...